{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Active+Comparator+%28Product-B%29&page=16",
    "query": {
      "intervention": "Active Comparator (Product-B)",
      "page": 16
    },
    "page_size": 10
  },
  "pagination": {
    "page": 16,
    "page_size": 10,
    "total_count": 618,
    "total_pages": 62,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Active+Comparator+%28Product-B%29&page=17&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Active+Comparator+%28Product-B%29&page=15&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T08:03:08.822Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07212803",
      "title": "Effects of Energy Drinks on Cardiovascular Endpoints",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Healthy Volunteers",
        "Safety After Oral Intake"
      ],
      "interventions": [
        {
          "name": "Energy Drink A + Placebo Capsule",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo Drink + Moxifloxacin Capsule",
          "type": "DRUG"
        },
        {
          "name": "Placebo Drink + Caffeine Capsule",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo Drink + Placebo Capsule",
          "type": "OTHER"
        },
        {
          "name": "Energy Drink B",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Control Product + Taurine",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Control Product + Caffeine + Taurine",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Lower Dose Energy Drink A",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of the Pacific",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 3,
      "start_date": "2025-11-01",
      "completion_date": "2026-09",
      "has_results": false,
      "last_update_posted_date": "2025-11-26",
      "last_synced_at": "2026-11-19T08:03:08.822Z",
      "location_count": 1,
      "location_summary": "Stockton, California",
      "locations": [
        {
          "city": "Stockton",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07212803"
    },
    {
      "nct_id": "NCT00841477",
      "title": "An Hepatitis B Vaccine Model for HIV Vaccine Trials in Drug Users",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hepatitis B Infection",
        "Hepatitis C Infection",
        "HIV Infection"
      ],
      "interventions": [
        {
          "name": "hepatitis B vaccine 3 dose schedule (0,1,2 month)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "HBV Vaccination Self-Efficacy Intervention",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "BEHAVIORAL"
      ],
      "sponsor": "National Institute on Drug Abuse (NIDA)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1260,
      "start_date": "2004-01",
      "completion_date": "2009-12",
      "has_results": false,
      "last_update_posted_date": "2017-01-11",
      "last_synced_at": "2026-11-19T08:03:08.822Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00841477"
    },
    {
      "nct_id": "NCT03948581",
      "title": "A Pilot Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Needle Safety Device (PFS+NSD) in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Vedolizumab SC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 102,
      "start_date": "2018-02-21",
      "completion_date": "2018-09-21",
      "has_results": true,
      "last_update_posted_date": "2022-07-29",
      "last_synced_at": "2026-11-19T08:03:08.822Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03948581"
    },
    {
      "nct_id": "NCT00753467",
      "title": "A Phase II Study to Determine the Safety and Efficacy of Interferon-gamma in Patients With Chronic Hepatitis B",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis B"
      ],
      "interventions": [
        {
          "name": "IFN-γ 1b (Actimmune)",
          "type": "DRUG"
        },
        {
          "name": "Adefovir dipivoxil",
          "type": "DRUG"
        },
        {
          "name": "IFN-γ 1b and Adefovir dipivoxil combination",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Huntington Medical Research Institutes",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 30,
      "start_date": "2008-09",
      "completion_date": "2009-08",
      "has_results": false,
      "last_update_posted_date": "2010-10-21",
      "last_synced_at": "2026-11-19T08:03:08.822Z",
      "location_count": 1,
      "location_summary": "Pasadena, California",
      "locations": [
        {
          "city": "Pasadena",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00753467"
    },
    {
      "nct_id": "NCT03677596",
      "title": "A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Leukemia",
        "Precursor b-Cell Lymphoblastic Leukemia-Lymphoma",
        "ACUTE LYMPHOBLASTIC LEUKEMIA"
      ],
      "interventions": [
        {
          "name": "inotuzumab ozogamicin-dose level 2",
          "type": "DRUG"
        },
        {
          "name": "Inotuzumab ozogamicin-dose level 1",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 102,
      "start_date": "2019-07-01",
      "completion_date": "2023-05-26",
      "has_results": true,
      "last_update_posted_date": "2023-11-22",
      "last_synced_at": "2026-11-19T08:03:08.822Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03677596"
    },
    {
      "nct_id": "NCT01268215",
      "title": "Pilot Study of Topical Steroid for Prevention of Chronic Lung Disease in Extremely Premature Infants.",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bronchopulmonary Dysplasia"
      ],
      "interventions": [
        {
          "name": "Infasurf",
          "type": "DRUG"
        },
        {
          "name": "Pulmicort",
          "type": "DRUG"
        },
        {
          "name": "Sham",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "East Carolina University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "24 Weeks",
        "maximum_age": "28 Weeks",
        "sex": "ALL",
        "summary": "24 Weeks to 28 Weeks"
      },
      "enrollment_count": 45,
      "start_date": "2010-07",
      "completion_date": "2013-12",
      "has_results": false,
      "last_update_posted_date": "2010-12-29",
      "last_synced_at": "2026-11-19T08:03:08.822Z",
      "location_count": 1,
      "location_summary": "Greenville, North Carolina",
      "locations": [
        {
          "city": "Greenville",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01268215"
    },
    {
      "nct_id": "NCT05184335",
      "title": "Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Brilaroxazine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Reviva Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 690,
      "start_date": "2022-01-24",
      "completion_date": "2025-02",
      "has_results": false,
      "last_update_posted_date": "2024-12-19",
      "last_synced_at": "2026-11-19T08:03:08.822Z",
      "location_count": 18,
      "location_summary": "Phoenix, Arizona • Bentonville, Arkansas • Little Rock, Arkansas + 14 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Bentonville",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05184335"
    },
    {
      "nct_id": "NCT00833378",
      "title": "Drug Interaction Study Between Eltrombopag and Lopinavir/Ritonavir in Healthy Adult Subjects.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "Eltrombopag",
          "type": "DRUG"
        },
        {
          "name": "Lopinavir/Ritonavir",
          "type": "DRUG"
        },
        {
          "name": "Eltrombopag and Lopinavir/Ritonavir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 40,
      "start_date": "2009-01-19",
      "completion_date": "2009-03-11",
      "has_results": false,
      "last_update_posted_date": "2017-11-14",
      "last_synced_at": "2026-11-19T08:03:08.822Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00833378"
    },
    {
      "nct_id": "NCT06333808",
      "title": "Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV-1-infection"
      ],
      "interventions": [
        {
          "name": "Bictegravir/Lenacapavir (BIC/LEN) FDC",
          "type": "DRUG"
        },
        {
          "name": "Lenacapavir",
          "type": "DRUG"
        },
        {
          "name": "B/F/TAF",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match B/F/TAF",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match BIC/LEN FDC",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match Lenacapavir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 577,
      "start_date": "2024-03-25",
      "completion_date": "2029-12",
      "has_results": true,
      "last_update_posted_date": "2026-11-05",
      "last_synced_at": "2026-11-19T08:03:08.822Z",
      "location_count": 51,
      "location_summary": "Phoenix, Arizona • Berkeley, California • Beverly Hills, California + 43 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06333808"
    },
    {
      "nct_id": "NCT00004859",
      "title": "Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "thalidomide",
          "type": "DRUG"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 589,
      "start_date": "2000-01",
      "completion_date": "2010-03",
      "has_results": true,
      "last_update_posted_date": "2014-06-02",
      "last_synced_at": "2026-11-19T08:03:08.822Z",
      "location_count": 235,
      "location_summary": "Fort Smith, Arkansas • Modesto, California • Salinas, California + 168 more",
      "locations": [
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "Modesto",
          "state": "California"
        },
        {
          "city": "Salinas",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004859"
    }
  ]
}